Chong Boon Teo1, Pek Yan Tan1, Ryan Yong Kiat Tay1, Joan Khoo2, Gerald F Watts3,4, Wann Jia Loh5. 1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Department of Endocrinology, Changi General Hospital, Singapore, Singapore. 3. School of Medicine, University of Western Australia, Perth, Australia. 4. Department of Cardiology, Royal Perth Hospital, Perth, Australia. 5. Department of Endocrinology, Changi General Hospital, Singapore, Singapore. loh.wann.jia@singhealth.com.sg.
Abstract
INTRODUCTION: Although low vitamin D levels are associated with statin-associated muscle symptoms (SAMS), it remains unclear if vitamin D supplementation leads to symptom improvement. AIM: We performed a systematic review to evaluate the association of vitamin D supplementation with resolution of SAMS. METHODS: We searched Medline (PubMed), Embase and Cochrane Library till 12 December 2021. Full length articles that reported on the association between vitamin D supplementation in adult patients with SAMS were included. RESULTS: We identified 8 interventional studies comprising 669 participants. Majority of the participants were of Caucasian ethnicity and the mean age of participants ranged from 59.5 to 64.8 years old. The studies recruited patients with initial mean pre-treatment vitamin D levels ranging from 17.8 to 22.0ng/mL. Follow up duration ranged from 2 to 24 months and mean post-treatment vitamin D levels ranged from 34.3 to 56.0ng/mL. We found that vitamin D supplementation was associated with improved statin tolerance in 509 out of 606 (83.9%) patients across the 7 studies which reported patient numbers after supplementation (95% CI = 0.81-0.87, I2 = 72% n = 7). None of the studies were randomized controlled trials (RCTs) and hence placebo effect of vitamin D could not be ruled out. Nocebo effect of statin was also not assessed by any of the studies. CONCLUSION: Vitamin D supplementation in patients with mild-moderate vitamin D insufficiency was associated with improvement of SAMS. However, quantitative efficacy analysis was not possible and this observed association is likely confounded by nocebo and placebo effects. RCTs are required to conclusively assess the utility of vitamin D supplementation in improving SAMS.
INTRODUCTION: Although low vitamin D levels are associated with statin-associated muscle symptoms (SAMS), it remains unclear if vitamin D supplementation leads to symptom improvement. AIM: We performed a systematic review to evaluate the association of vitamin D supplementation with resolution of SAMS. METHODS: We searched Medline (PubMed), Embase and Cochrane Library till 12 December 2021. Full length articles that reported on the association between vitamin D supplementation in adult patients with SAMS were included. RESULTS: We identified 8 interventional studies comprising 669 participants. Majority of the participants were of Caucasian ethnicity and the mean age of participants ranged from 59.5 to 64.8 years old. The studies recruited patients with initial mean pre-treatment vitamin D levels ranging from 17.8 to 22.0ng/mL. Follow up duration ranged from 2 to 24 months and mean post-treatment vitamin D levels ranged from 34.3 to 56.0ng/mL. We found that vitamin D supplementation was associated with improved statin tolerance in 509 out of 606 (83.9%) patients across the 7 studies which reported patient numbers after supplementation (95% CI = 0.81-0.87, I2 = 72% n = 7). None of the studies were randomized controlled trials (RCTs) and hence placebo effect of vitamin D could not be ruled out. Nocebo effect of statin was also not assessed by any of the studies. CONCLUSION: Vitamin D supplementation in patients with mild-moderate vitamin D insufficiency was associated with improvement of SAMS. However, quantitative efficacy analysis was not possible and this observed association is likely confounded by nocebo and placebo effects. RCTs are required to conclusively assess the utility of vitamin D supplementation in improving SAMS.
Authors: Charles J Glueck; Shaaista B Budhani; Silpa S Masineni; Cesar Abuchaibe; Naseer Khan; Ping Wang; Naila Goldenberg Journal: Curr Med Res Opin Date: 2011-07-06 Impact factor: 2.580
Authors: Alison L P Compton; Marc J Pepin; Daniel R Katzenberger; Debra W Kemp; Jamie N Brown Journal: Ann Pharmacother Date: 2020-10-15 Impact factor: 3.154
Authors: Ajay Gupta; David Thompson; Andrew Whitehouse; Tim Collier; Bjorn Dahlof; Neil Poulter; Rory Collins; Peter Sever Journal: Lancet Date: 2017-05-02 Impact factor: 79.321
Authors: Maciej Banach; Manfredi Rizzo; Peter P Toth; Michel Farnier; Michael H Davidson; Khalid Al-Rasadi; Wilbert S Aronow; Vasilis Athyros; Dragan M Djuric; Marat V Ezhov; Robert S Greenfield; G Kees Hovingh; Karam Kostner; Corina Serban; Daniel Lighezan; Zlatko Fras; Patrick M Moriarty; Paul Muntner; Assen Goudev; Richard Ceska; Stephen J Nicholls; Marlena Broncel; Dragana Nikolic; Daniel Pella; Raman Puri; Jacek Rysz; Nathan D Wong; Laszlo Bajnok; Steven R Jones; Kausik K Ray; Dimitri P Mikhailidis Journal: Arch Med Sci Date: 2015-03-14 Impact factor: 3.318
Authors: Vybhav Jetty; Charles J Glueck; Ping Wang; Parth Shah; Marloe Prince; Kevin Lee; Michael Goldenberg; Ashwin Kumar Journal: N Am J Med Sci Date: 2016-03